BioMarin’s Hemophilia Gene Therapy Among Nine Products On Track For EU-Wide Approval

Four orphan drugs and a new COVID-19 vaccine are among the latest products that the European Medicines Agency says should be approved.

Blood Sample for Factor VIII. Blood coagulation testing. Medical or health concept. coagulation factor test. Antihemophilic factor A test
Hemophilia A Patients Need Frequent Injections To Replace The Missing Factor VIII Blood Clotting Protein • Source: Shutterstock

BioMarin Pharmaceutical’s Roctavian (valoctocogene roxaparvovec) is on track to be approved as the first gene therapy in the EU for hemophilia A, after the European Medicines Agency recommended that it be granted a conditional marketing authorization.

Roctavian is intended as a one-time infusion for treating severe hemophilia A in adult patients who do not have factor...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography